Mission:
|
 |
|
Contract research and technology development focused on cell-based and in vivo applications of RNAi, miRNA modulation and high content phenotyping to accelerate the discovery and validation of novel therapeutic targets and pre-clinical development of emerging drug candidates
|
|
Workforce, operations (July 2011): |
| |
|
Cenix BioScience GmbH: 37 staff in 900 m2 (7,200 sq feet) labs and offices in the BIOZ research center (Dresden,
Germany)
|
|
Cenix BioScience Belgium bvba: 4 staff on Janssen Pharmaceutica campus in Beerse, Flanders, Belgium
|
Privately owned GmbH, founded on 26 October 1999
& bvba subsidiary, founded on 17 March 2011 |
| |
|
Parent Institutes: |
|
|
European Molecular Biology
Laboratory (EMBL, Heidelberg, Germany) |
|
|
Max Planck Institute for Molecular Cell
Biology and Genetics (MPI-CBG, Dresden, Germany) |
|
|
The Wellcome Trust Sanger Centre
(Hinxton, UK) |
|
|
The BC Cancer Agency (Vancouver,
Canada) |
| |
|
Scientific
Founders: |
|
|
Dr. Christophe J. Echeverri
(lead founder, CEO/CSO) |
|
|
Prof. Dr. Anthony A. Hyman
(Director at MPI-CBG) |
|
|
Dr. Pierre Gönczy
(Associate Scientist at ISREC) |
|
| Started-up
with 2 rounds of VC financing, now fully self-sustaining since 2003 |
| |
|
Financing Round 1A:
September 2000 (€ 3.5 Mio) |
|
|
Heidelberg Innovation
(Heidelberg, Germany) |
|
|
TechnoStart (Ludwigsburg,
Germany) |
|
|
tbg
(Bonn, Germany) |
| |
|
Financing Round 1B:
June 2002 (€ 3.5 Mio) |
|
|
EMBL Ventures (Heidelberg,
Germany) |
|
|
Heidelberg Innovation
(Heidelberg, Germany) |
|
|
Sunstone Capital (Copenhagen,
Denmark) |
|
|
TechnoStart (Ludwigsburg,
Germany) |
| |
|
Key clients & partners to date: |
|
|
Alnylam Pharmaceuticals (Cambridge,
MA) |
|
|
Applied Biosystems/Ambion (Austin,
TX) |
|
|
AstraZeneca (Waltham, MA) |
|
|
Bayer HealthCare AG
(Leverkusen, Germany; now Bayer-Schering)
|
|
|
Boehringer Ingelheim
(Biberach, Germany)
|
|
|
|
|
|
Instituto de Medicina Molecular
(Lisbon, Portugal) |
|
|
Janssen Research & Development, Janssen Pharmaceutica NV,
(Beerse, Belgium)
|
|
|
Merck KGaA (Darmstadt, Germany) |
|
|
Regulus Therapeutics (Carlsbad,
CA) |
|
|
Schering AG (Berlin, Germany; now
Bayer-Schering) |
|
|
Siena Biotech (Siena, Italy) |
Recognized scientific leader in HT-RNAi and High Content
screening:
|
|
Pioneering work
on convergence of HT-RNAi screening with High Content phenotyping: |
|
|
Gönczy et al., 2000, Nature 408: 331
Sönnichsen et al., 2005, Nature 434: 462
|
|
Strong
publication record in top-tier scientific journals: |
|
|
Gunsalus et al., 2005, Nature 436: 861
Pelkmans et al., 2005, Nature 436: 78
Echeverri & Perrimon, 2006, Nature Rev. Genetics 7:
373
Echeverri et al., 2006, Nature Methods 3: 777
Gottwein et al., 2007, Nature 450: 1096
Kittler et al., 2007, Nature Methods 4: 337
Rodrigues et al., 2008, Cell Host & Microbes 4:
209
Prudêncio et al., 2008, PLoS Pathogens 4:
e1000201
|
